Shots: Forty Seven to receive ~ $15.8M up front, ~$104M as development and commercial milestones and royalties on sales of 5F9 in selected territories and will retain WW rights of […]readmore
Tags : ONO Pharmaceutical
Shots: Cancer Research and LifeArc to receive upfront, milestones and royalties on sales of products. Ono to get an option to license the developed product with exclusive WW commercialization rights […]readmore
Shots: The P-III ATTRACTION-3 study involves assessing of Opdivo (involumab, IV) vs CT (docetaxel/paclitaxel) in patients with unresectable advanced or recurrent esophageal cancer or intolerant to fluoropyrimidine + PT-based drug […]readmore